This comprehensive bone marrow assessment combines aspiration and trephine biopsy to examine cell morphology, tissue architecture, and cellularity. If initial findings warrant, immunohistochemical staining with 3 markers is performed to further characterize cell types and aid in diagnosing various blood disorders and cancers.

Bone marrow aspiration is a procedure where a small amount of the liquid portion of bone marrow is extracted using a needle. This sample is examined to analyze the types and numbers of blood cells present, assess their maturity, and identify any abnormal cells. It is used to diagnose various blood disorders, including leukemia, lymphoma, and anemias.

A trephine biopsy is a procedure where a small, cylindrical sample of bone marrow is removed using a hollow needle. This sample provides a detailed view of the bone marrow’s architecture, cellularity, and any abnormalities present. It’s crucial for diagnosing various blood disorders and cancers, including leukemia, lymphoma, and myelodysplastic syndromes.

This test uses a panel of antibodies to identify and quantify specific cell populations in blood, bone marrow, or other body fluids. It helps diagnose and classify different types of leukemias and lymphomas, assess disease progression, and monitor response to treatment.

This comprehensive bone marrow assessment combines aspiration of the liquid portion to analyze cell morphology and conduct flow cytometry with a trephine biopsy to examine tissue architecture and cellularity. Additionally, a leukemia/lymphoma flow cytometry panel identifies and quantifies specific cell populations, aiding in the diagnosis and management of hematological malignancies.

Minimal Residual Disease (MRD) Flow Cytometry is a highly sensitive test used to detect and quantify small numbers of cancer cells remaining after treatment in blood cancers like leukemia and lymphoma. It uses fluorescently labeled antibodies to identify specific cell surface markers on leukemia/lymphoma cells, even when present in very low numbers. MRD flow cytometry helps assess treatment response, predict relapse risk, and guide further treatment decisions.

Stem Cell Enumeration is a flow cytometry test that quantifies the number of hematopoietic stem cells (HSCs) in blood or bone marrow samples. It measures the percentage and absolute count of CD34+ cells, a marker for HSCs. This test is essential for assessing stem cell transplant eligibility, monitoring mobilization efficacy, and evaluating stem cell product quality.

Trephine Diagnostic IHC Panel is a specialized immunohistochemistry test performed on bone marrow biopsy samples (trephine). It uses a panel of antibodies to identify and characterize various cell types within the bone marrow. This aids in diagnosing and classifying blood cancers (leukemias, lymphomas), bone marrow disorders (myelodysplastic syndromes, myeloproliferative neoplasms), and other conditions affecting the bone marrow microenvironment.

This test uses an antibody to detect the presence and localization of a specific protein within a tissue sample. This protein (marker) can help identify the type and origin of cells, aid in cancer diagnosis, classify tumors, and guide treatment decisions.

This test uses antibodies to detect the presence and localization of three specific proteins within a tissue sample. These proteins (markers) can help identify the type and origin of cells, aid in cancer diagnosis, classify tumors, and guide treatment decisions.